arrow
D

Daria M. Grousova

ministry of health of the russian federation
H指数:12
被引数:3,346

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A Lethal Pseudofilovirus Model in Ifnar1(-/-) Mice Using Recombinant Vesicular Stomatitis Viruses

利用重组水泡性口炎病毒在Ifnar1(-/-)小鼠中建立的致死性假丝病毒模型

2026-08-110
OA
Long-term protective potency of AAV vector-based SARS-CoV-2 prophylaxis in mice and non-human primates

AAV载体介导的SARS-CoV-2预防措施的长期保护效力在小鼠和非人灵长类动物中的研究

2026-06-010
OA
Structural Design of T-Cell Epitope-Based mRNA Vaccine Constructs Determines the Quality of T-Cell Immunity and Protective Efficacy Against SARS-CoV-2 in Mice

基于T细胞表位的mRNA疫苗构建体的结构设计决定了T细胞免疫的质量以及小鼠中对抗SARS-CoV-2的保护效力

2026-04-040
OAAI
Sputnik V update: safety and neutralizing antibodies in healthy adults and adolescents

卫星V疫苗更新:健康成人和青少年中的安全性与中和抗体

2026-03-270
OA
Broadly neutralizing single-domain antibody targeting the spike NTD displays therapeutic efficacy against diverse SARS-CoV-2 variants

靶向spike NTD的广泛中和单域抗体显示对多种SARS-CoV-2变体的治疗效果

2026-03-270
OAAI
Adenoviral Vectors Expressing Optimized preM/E Genes of WNV Deliver Long-Term Protection Against Lethal West Nile Virus Challenge

表达优化后WNV preM/E基因的腺病毒载体可提供对致死性西尼罗病毒攻击的长期保护

2025-11-210
OAAI
Safety and immunogenicity of GamEvac-Combi, a heterologous rVSV- and rAd5-vectored Ebola vaccine: a randomized controlled multicenter clinical trial in the Republic of Guinea and Russia

GamEvac-Combi,一种异源rVSV-和rAd5载体埃博拉疫苗的安全性与免疫原性:一项在几内亚共和国和俄罗斯进行的随机对照多中心临床试验

2025-03-200
OA
Immunogenicity and Protectivity of Sputnik V Vaccine in hACE2-Transgenic Mice against Homologous and Heterologous SARS-CoV-2 Lineages Including Far-Distanced Omicron BA.5

Sputnik V疫苗在hACE2-Transgenic小鼠中针对同源和异源SARS-CoV-2谱系 (包括远距离Omicron BA.5) 的免疫原性和保护性

2024-10-080
OAAI
Safety and immunogenicity of rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine against SARS-CoV-2 in healthy adolescents: an open-label, non-randomized, multicenter, phase 1/2, dose-escalation study

基于rAd26和rAd5载体的异源初免-加强新型冠状病毒肺炎疫苗对健康青少年SARS-CoV-2的安全性和免疫原性: 一项开放标签、非随机、多中心、1/2期、剂量递增研究

2023-08-014
OAAI
rAAV expressing recombinant antibody for emergency prevention and long-term prophylaxis of COVID-19
2023-03-306
OAAI
Estimation of anti-orthopoxvirus immunity in Moscow residents and potential risks of spreading Monkeypox virus
2022-11-166
OAAI
Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates

鼻内递送的基于载体的异源启动-加强新型冠状病毒肺炎疫苗Sputnik V在小鼠和非人灵长类动物中的免疫原性和保护性

2022-09-2610
OAAI
Retention of Neutralizing Response against SARS-CoV-2 Omicron Variant in Sputnik V-Vaccinated Individuals

在Sputnik V疫苗接种的个体中保留针对SARS-CoV-2 Omicron变体的中和反应

2022-05-2120
OAAI
An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine Sputnik Light for prevention of coronavirus infection in healthy adults
2021-12-0142
OAAI
Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants

Sputnik V疫苗接种人群的血清对关注变体 (VOC: B.1.1.7,B.1.351,P.1,B.1.617.2,B.1.617.3) 和莫斯科地方性SARS-CoV-2变体的中和活性

2021-07-1288
OAAI
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

基于rAd26和rAd5载体的异源启动-加强新型冠状病毒肺炎疫苗的安全性和有效性: 俄罗斯一项随机对照3期试验的中期分析

LANCET
IF88.5
2021-02-011.2K
OAAI
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

两种制剂中基于rAd26和rAd5载体的异源启动-加强新型冠状病毒肺炎疫苗的安全性和免疫原性: 来自俄罗斯的两项开放,非随机1/2期研究

LANCET
IF88.5
2020-09-01732
OAAI